Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says

Executive Summary

Wyeth expects to have about one year to switch Effexor XR patients to its follow-on serotonin and norepinephrine reuptake inhibitor DVS-233 before venlafaxine XR loses market exclusivity in 2008
Advertisement

Related Content

WHI Premarin Data Will Not Affect Bazedoxifene Phase III Studies, Wyeth Says
Premarin WHI Results May Mean Additional Labeling Changes, FDA Says
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Advertisement
UsernamePublicRestriction

Register

PS044106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel